Abstract 3248
Background
Metastatic esophagogastric cancer patients can be treated with paclitaxel/ramucirumab, or another taxane, or an irinotecan-containing regimen in second line. The aim of this study was to explore the real-world use of second-line palliative systemic treatment in esophagogastric cancer and to compare treatment regimens in terms of overall survival (OS) and time to failure of second-line treatment (TTF).
Methods
Synchronous metastatic esophagogastric cancer patients treated with systemic therapy (2010-2015) were selected from the nationwide Netherlands Cancer Registry. Systemic treatment was considered second line if a drug group was used that essentially differed from first-line treatment, irrespective of reason for switch of treatment. Thus, a switch from capecitabine/oxaliplatin (CapOx) to docetaxel was considered second line, while CapOx to i.v. 5-fluorouracil (5-FU)/oxaliplatin was not. OS and TTF were calculated from start of second-line treatment until date of death, or progression/failure of treatment, and analyzed using Kaplan Meier curves with logrank test.
Results
Second-line systemic treatment was applied in 344 (20%) of the 1712 patients that received first-line systemic treatment in 2010-2015, of which 96% had adenocarcinoma and 4% squamous cell carcinoma. In the total cohort, 38 different second-line systemic treatment regimens were administered. Monotherapy with a taxane (31%), paclitaxel/ramucirumab (13%), carboplatin/paclitaxel (10%), trastuzumab-containing regimens (7%), fluoropyrimidine/platinum doublets (7%), irinotecan (6%), and 5-FU/irinotecan (6%) were most frequently used regimens. In patients that received second-line treatment, median OS was 5.2 (IQR 2.7, 8.6) and TTF 2.8 (IQR 1.5, 5.0) months. Median OS was 3.9 (IQR 2.3, 6.4) months in patients treated with second-line taxane monotherapy (n = 108), and 5.4 (IQR 2.3, 9.7) months in patients treated with paclitaxel/ramucirumab (n = 45, p = 0.188).
Conclusions
According to real-world evidence, 20% of synchronous metastatic esophagogastric cancer patients treated with first-line systemic therapy receive second-line systemic treatment, most frequently consisting of a taxane with or without ramucirumab.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Lilly.
Disclosure
R.H.A. Verhoeven: Research grant / Funding (institution): Roche; Research grant / Funding (institution): BMS. N. Haj Mohammad: Advisory / Consultancy: BMS; Advisory / Consultancy: MSD. J. de Vos-Geelen: Non-remunerated activity/ies: BTG; Research grant / Funding (institution), Non-remunerated activity/ies: Servier; Advisory / Consultancy: Shire. T. Van Voorthuizen: Non-remunerated activity/ies: Astellas; Non-remunerated activity/ies: Ipsen; Non-remunerated activity/ies: Roche; Non-remunerated activity/ies: Bayer. M. van Oijen: Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Nordic; Research grant / Funding (institution): Merck Serono; Research grant / Funding (institution): Servier; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Roche. H.W.M. van Laarhoven: Research grant / Funding (institution): Bayer; Advisory / Consultancy, Research grant / Funding (institution): BMS; Advisory / Consultancy, Research grant / Funding (institution): Celgene; Advisory / Consultancy, Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Merck Serono; Research grant / Funding (institution): MSD; Advisory / Consultancy, Research grant / Funding (institution): Nordic; Research grant / Funding (institution): Philips; Research grant / Funding (institution): Roche. All other authors have declared no conflicts of interest.
Resources from the same session
3159 - Anlotinib for advanced hepatocellular carcinoma: interim results from the phase II ALTER0802 study
Presenter: AiPing Zhou
Session: Poster Display session 2
Resources:
Abstract
3191 - The efficacy and safety of lenvatinib in patients who did not meet the inclusion criteria of the phase 3 trial (REFLECT trial) and those with BCLC Stage B hepatocellular carcinoma - A nationwide multicenter study in Japan-
Presenter: Azusa Sakamoto
Session: Poster Display session 2
Resources:
Abstract
1529 - Prognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase 3 studies (REACH, REACH-2)
Presenter: Andrew Zhu
Session: Poster Display session 2
Resources:
Abstract
2767 - Effect of second-line cabozantinib on health states for patients with advanced hepatocellular carcinoma (aHCC) after sorafenib: QTWiST analysis from the CELESTIAL study
Presenter: Nicholas Freemantle
Session: Poster Display session 2
Resources:
Abstract
2150 - Alpha-fetoprotein (AFP) response in patients with unresectable hepatocellular carcinoma (HCC) in the phase 3 RESORCE trial
Presenter: Jordi Bruix
Session: Poster Display session 2
Resources:
Abstract
3437 - Phase I/II trial of NBTXR3 activated by SBRT in patients with hepatocellular carcinoma or liver metastasis
Presenter: Marc Pracht
Session: Poster Display session 2
Resources:
Abstract
1758 - Efficacy and safety of ramucirumab (RAM) for advanced hepatocellular carcinoma (HCC) with elevated alpha-fetoprotein (AFP) following first-line sorafenib across age subgroups in two global phase 3 trials (REACH and REACH-2)
Presenter: Masatoshi Kudo
Session: Poster Display session 2
Resources:
Abstract
1192 - Ramucirumab in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): An exposure–response analysis
Presenter: Josep Llovet
Session: Poster Display session 2
Resources:
Abstract
1600 - Outcomes of Hepatocellular Carcinoma (HCC) Patients Treated with Nivolumab: The Mount Sinai Hospital Experience.
Presenter: Sirish Dharmapuri
Session: Poster Display session 2
Resources:
Abstract
2364 - Pembrolizumab vs Chemotherapy in Patients With Advanced/Metastatic Adenocarcinoma (AC) or Squamous Cell Carcinoma (SCC) of the Esophagus as Second-Line Therapy: Analysis of the Chinese Subgroup in KEYNOTE-181
Presenter: Jia Chen
Session: Poster Display session 2
Resources:
Abstract